Quarterly ResultMay 12, 2026, 04:06 PM
Nyxoah Q1 Net Revenue 6.4M, U.S. Revenue +25% Seq; FY26 Guidance
AI Summary
Nyxoah reported strong first quarter 2026 financial and operating results, driven by the Genio launch in the U.S. U.S. net revenue grew 25% sequentially to 4.3 million, contributing to a global net revenue of 6.4 million, up 13% sequentially. The company achieved 100% prior-authorization approval on reviewed U.S. submissions and saw continued clarity in reimbursement. Nyxoah also provided full-year 2026 guidance, expecting worldwide net revenue between 36 million and 40 million.
Key Highlights
- Global net revenue for Q1 2026 was 6.4 million, a 13% sequential increase over Q4 2025.
- U.S. net revenue reached 4.3 million in Q1 2026, marking a 25% sequential growth.
- Gross profit was 3.6 million with a gross margin of 57% in Q1 2026.
- Cash, cash equivalents, and financial assets totaled 25.9 million as of March 31, 2026.
- The company trained 62 new surgeons and activated 34 new accounts in Q1.
- Nyxoah expects Q2 2026 U.S. net revenue to grow 25-30% sequentially.
- Full-year 2026 worldwide net revenue is projected to be 36 million to 40 million.
- Full-year 2026 gross margin is expected to be in the range of 60% to 62%.